Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Seres Therapeutics Yönetim
Yönetim kriter kontrolleri 3/4
Seres Therapeutics' CEO'su Eric Shaff, Jan2019 tarihinde atandı, in görev süresi 5.75 yıldır. in toplam yıllık tazminatı $ 3.16M olup, şirket hissesi ve opsiyonları dahil olmak üzere 21.7% maaş ve 78.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.096% ine doğrudan sahiptir ve bu hisseler $ 138.13K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.1 yıl ve 8.1 yıldır.
Anahtar bilgiler
Eric Shaff
İcra Kurulu Başkanı
US$3.2m
Toplam tazminat
| CEO maaş yüzdesi | 21.7% |
| CEO görev süresi | 5.8yrs |
| CEO sahipliği | 0.1% |
| Yönetim ortalama görev süresi | 5.1yrs |
| Yönetim Kurulu ortalama görev süresi | 8.1yrs |
Son yönetim güncellemeleri
Recent updates
Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade
Sep 23Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth
Jul 13
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth
May 08Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet
Mar 23Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns
Jan 30Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop
Dec 18Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop
Aug 31Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?
Aug 09Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?
Dec 28Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)
Sep 01Seres Therapeutics: What The Market Is Missing
Aug 19Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M
Aug 03Seres Therapeutics: The Good And The Challenging
Jul 12Seres Therapeutics stock slips on $100M stock offering
Jun 30Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?
Jun 16Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens
Jun 09Seres Therapeutics Is Playing A Long Game
Mar 06Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt
Dec 27Seres Therapeutics Molecular Data On SER-109 Looks Good
Oct 04Seres Therapeutics: Here We Go Again
Sep 09CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$162m |
| Mar 31 2024 | n/a | n/a | -US$83m |
| Dec 31 2023 | US$3m | US$685k | -US$114m |
| Sep 30 2023 | n/a | n/a | -US$141m |
| Jun 30 2023 | n/a | n/a | -US$153m |
| Mar 31 2023 | n/a | n/a | -US$265m |
| Dec 31 2022 | US$4m | US$662k | -US$250m |
| Sep 30 2022 | n/a | n/a | -US$231m |
| Jun 30 2022 | n/a | n/a | -US$103m |
| Mar 31 2022 | n/a | n/a | -US$87m |
| Dec 31 2021 | US$10m | US$625k | -US$66m |
| Sep 30 2021 | n/a | n/a | -US$34m |
| Jun 30 2021 | n/a | n/a | -US$132m |
| Mar 31 2021 | n/a | n/a | -US$105m |
| Dec 31 2020 | US$3m | US$590k | -US$89m |
| Sep 30 2020 | n/a | n/a | -US$90m |
| Jun 30 2020 | n/a | n/a | -US$76m |
| Mar 31 2020 | n/a | n/a | -US$66m |
| Dec 31 2019 | US$2m | US$540k | -US$70m |
| Sep 30 2019 | n/a | n/a | -US$73m |
| Jun 30 2019 | n/a | n/a | -US$78m |
| Mar 31 2019 | n/a | n/a | -US$95m |
| Dec 31 2018 | US$1m | US$435k | -US$99m |
| Sep 30 2018 | n/a | n/a | -US$107m |
| Jun 30 2018 | n/a | n/a | -US$92m |
| Mar 31 2018 | n/a | n/a | -US$92m |
| Dec 31 2017 | US$2m | US$377k | -US$89m |
Tazminat ve Piyasa: Eric 'nin toplam tazminatı ($USD 3.16M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).
Tazminat ve Kazançlar: Eric 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Eric Shaff (48 yo)
5.8yrs
Görev süresi
US$3,158,336
Tazminat
Mr. Eric D. Shaff, M.B.A., serves as President and Chief Executive Officer at Seres Therapeutics, Inc. since January 15, 2019 and serves as its Director since January 2019. He served as Chief Operating Off...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 5.8yrs | US$3.16m | 0.096% $ 113.1k | |
| Executive VP & Chief Medical Officer | 4.6yrs | US$1.57m | 0.014% $ 16.3k | |
| Executive VP and Chief Commercial & Strategy Officer | 4.3yrs | US$1.82m | 0.053% $ 62.0k | |
| Executive VP & CFO | less than a year | Veri yok | Veri yok | |
| Executive VP & Chief Technology Officer | 4yrs | US$5.32m | 0.051% $ 60.1k | |
| Executive VP & Chief Scientific Officer | 5.7yrs | US$1.67m | 0.044% $ 52.1k | |
| Investor Relations Officer | 8.9yrs | Veri yok | Veri yok | |
| Chief Legal Officer | 8.4yrs | US$1.44m | 0.082% $ 96.2k | |
| Assistant General Counsel | no data | Veri yok | Veri yok |
5.1yrs
Ortalama Görev Süresi
57yo
Ortalama Yaş
Deneyimli Yönetim: MCRB 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.1 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 5.8yrs | US$3.16m | 0.096% $ 113.1k | |
| Independent Director | 7.3yrs | US$225.23k | 0.021% $ 24.6k | |
| Independent Director | 9.5yrs | US$222.27k | 0% $ 0 | |
| Independent Director | 8.9yrs | US$219.23k | 0% $ 0 | |
| Independent Director | 10yrs | US$232.69k | 0.042% $ 49.2k | |
| Member of Scientific Advisory Board | 9.8yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 4.6yrs | US$211.73k | 0.031% $ 36.9k | |
| Independent Chairman | 5.2yrs | US$249.23k | 0.0024% $ 2.8k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok |
8.1yrs
Ortalama Görev Süresi
63yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: MCRB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.1 yıldır).